BJH - volume 6, issue Abstract Book BHS, january 2015
A. Van De Velde MD, PhD, S. Anguille MD, PhD, P. Beutels , S. Dom , I. Cornille , G. Nijs , F. van Tendeloo , E.L. Smits , A. Verlinden MD, A.P. Gadisseur , W.A. Schroyens , Z.N. Berneman MD, PhD
BJH - volume 5, issue 4, december 2014
B. Hodossy MD, I. Vrelust MD, S. Anguille MD, PhD, V. Van Marck MD, PhD, M. Maes PhD, PharmD, K. Vermeulen PhD, A. Van De Velde MD, PhD, A. Gadisseur MD, PhD, W. Schroyens MD, PhD, Z. Berneman MD, PhD
We present the case of a 58-year-old male patient with a long-standing, intermittent oedema of the lower extremities and significant spontaneous variations in haematocrit values. Repeated examinations failed to reveal a clear etiology until the patient suffered from a severely painful exacerbation of leg oedema and hypotension. Laboratory analysis showed hypoalbuminemia. The combination of oedema, hypotension, hypoalbuminemia and hemoconcentration was indicative of a systemic capillary leak syndrome. This condition is known to be associated with monoclonal gammopathy, as was the case in our patient. New investigations showed suspicious lesions in the nasopharynx, scrotum and breast. Biopsies of this breast mass as well as bone marrow biopsy showed the presence of an extranodal natural killer/T-cell lymphoma, nasal type. Polychemotherapy was administered according to the SMILE schedule leading to a remission after two cycles. The patient then underwent autologous hematopoietic stem cell transplantation. The patient is currently without signs of systemic capillary leak syndrome. This report illustrates that systemic capillary leak syndrome may occur as a prodrome of haematological malignancies, such as natural killer/T-cell lymphoma and documents that it is responsive to chemotherapy.
(BELG J HEMATOL 2014;5(4):148–53)
Read moreBJH - volume 4, issue 2, june 2013
S. Anguille MD, PhD, Z. Berneman MD, PhD
The prognosis of patients with acute myeloid leukaemia (AML) remains dismal, with a five year overall survival rate of only 5.2% for the continuously growing subgroup of AML patients older than 65 years. These patients are generally not considered eligible for intensive chemotherapy and/or allogeneic haematopoietic stem cell transplantation, emphasising the need for novel, less toxic treatment alternatives for the older-age category of AML patients. It is within this context that immunotherapy has gained attention in recent years. In this review, we focus on the use of dendritic cell (DC) vaccines for immunotherapy of AML. DCs are the central orchestrators of the immune system bridging innate and adaptive immunity and are critical to the induction of anti-leukaemia immunity. Here, we discuss the rationale and basic principles of DC-based therapy for AML and review the clinical experience that has been obtained so far with this form of immunotherapy in patients with AML.
(BELG J HEMATOL 2013;4(2):58–65)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
